朱伟
学院：437必赢会员中心
专业：病理学
职称：教授
简介：
朱伟，医学博士，三级教授，博士生导师，博士后合作导师。病理学技术教研室主任。现任广东省科学学与科技管理研究会医学研究专业委员会常务委员；广东省、浙江省、河南省和湖北省自然科学基金评审专家；教育部学位论文评审专家；湛江市医学会消化道肿瘤学分会第一届专业委员会常务委员；中华结直肠癌MDT联盟湛江地区分会常任委员；东莞市医学会病理学分会常务委员；广东分子病理学专业委员会委员。《Molecular Therapy - Nucleic Acids》、《Theranostics》等杂志审稿专家。
主要研究方向（1）结直肠癌等恶性肿瘤分子机制的研究；（2）结直肠癌等恶性肿瘤分子标志物的研究。主持国家自然科学基金面上项目1项、广东省自然科学基金4项、广东省普通高校特色创新项目1项等。第一/通讯作者发表SCI收录论文22篇，授权实用新型专利2项。近5年来指导的研究生获广东省优秀研究生2人次，国家奖学金3人次，骏腾病理研究生奖学金4人次；获437必赢会员中心2021年度研究生教育“优秀导师”称号。
科研项目
1.国家‒自然科学基金委面上项目（81472275），2015-2018，主持
2.广东省‒自然科学基金面上项目（2022A1515012171）,2022-2024，主持
2.广东省‒自然科学基金面上项目（2020A151501303）,2019-2022，主持
2.广东省‒自然科学基金面上项目（2014A030313542）,2014-2017，主持
代表性成果
[1] Cai MY*, Tong ZT*,Zhu W*, Wen ZZ, Rao HL, Kong LL, Guan XY, Kung HF, Zeng YX, Xie D#. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradio resistance in human nasopharyngeal carcinoma. Mol Med. 2011;17(11-12):1137-1145. (IF:5.9)
[2]Zhu W*, Cai MY*, Tong ZT*, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D#. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut. 2012; 61(4):562-75. (IF:10.6)
[3] AIJING XU*,WEI ZHU#, TANG LI, Li X, Cheng J, Li C, Yi P, Liu L#. Interleukin-10 gene transfer into insulin-producing β cells protects against diabetes in non-obese diabetic mice. Mol Med Rep. 2015; 12(3):3881-3889. (IF:1.559)
[4]Zhu W*, Li GX*, Chen HL, Liu XY#. The role of eukaryotic translation initiation factor 6 in tumors. Oncol Lett. 2017; 14(1):3-9. (IF:1.39)
[5]Wei Zhu*, Guixian LI*, Haina Guo, Chen H, Xu X, Long J, Zeng C, Wang X#. Clinicopathological significance of MTA 1 expression in patients with non-small cell lung cancer：A meta-analysis. Asian Pac J Cancer Prev. 2017; 18(11):2903-2909.
[6] Tang J, Yang Z, Wang Z, Li Z, Li H, Yin J, Deng M#,Zhu W#, Zeng C#. Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer. World J Surg Oncol. 2017; 15(1):173-177. (IF:1.6)
[7] Sun Y, Zeng C, Gan S, Li H, Cheng Y, Chen D, Li R,Zhu W#. LncRNA HOTTIP-Mediated HOXA11 Expression Promotes Cell Growth, Migration and Inhibits Cell Apoptosis in Breast Cancer. Int J Mol Sci. 2018; 19(2):1-12. (IF: 4.183)
[8] Sun Y*, Long J*, Yin Y, Li H, Jiang E, Zeng C#,Zhu W#. Characterization of CSF2A fusion gene and its effect on EBV+ tumor cells. J Med Virol. 2018; 90(2):1750-1756. (IF: 2.049)
[9] Yin Y*, Long J*, Sun Y, Li H, Jiang E, Zeng C#,Zhu W#. The function and clinical significance of eIF3 in cancer. Gene. 2018; 673:130-133. (IF: 2.638)
[10] Long J*, Yin Y*, Guo H, Li S, Sun Y, Zeng C#,Zhu W#. The mechanisms and clinical significance of PDCD4 in colorectal cancer. Gene. 2019; 680:59-64. (IF: 2. 984)
[11] Tian F*, Zhan Y*,Zhu W*, Li J, Tang M, Chen X, Jiang J. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Int J Mol Med. 2019;43(2):1058-1066. (IF: 3.098)
[12]WEI ZHU*, JIA-LI LONG*, YU-TING YIN, HAI-NA GUO, EN-PING JIANG, YU-LING LI, QING-LIAN HE, CHAO ZENG#, YAN-QIN SUN#. MicroRNA-34a suppresses the invasion and migration of colorectalcancercells by enhancing EGR1 and inhibiting vimentin. Experimental and Therapeutic Medicine. 2019; 18:2459-2466. (IF:1.785)
[13] Yuting Yin*, Jiali Long*, Qinglian He, Yuling Li, Yanqiu Liao, Peishan He,Wei Zhu#. Emerging roles of circRNA in formation and progression of cancer. Journal of Cancer. 2019; 10(21): 5015-5021. (IF: 3.565)
[14] Qinglian He*, Jiali Long*, Yuting Yin*, Yuling Li, Xue Lei, Ziqi Li,Wei Zhu#. Emerging Roles of lncRNAs in the Formation and Progression of Colorectal Cancer. Front. Oncol. 2020; 9(1542): 1-11. (IF: 6.244)
[15] Yuting Yin*, Qinglian He*, Yuling Li, Jiali Long, Xue Lei, Ziqi Li,Wei Zhu#.Emerging functions of PRKDC in the initiation and progression of cancer. Tumori J. 2020; 300891620950472. (IF: 2.098)
[16] Jiali Long*, Qinglian He*, Yuting Yin, Xue Lei, Ziqi Li,Wei Zhu#. The effect of miRNA and autophagy on colorectal cancer. Cell proliferation. 2020; 53(10): e12900. (IF: 6.831)
[17] Tian FQ*, Chen ZR*,Zhu W*, Tang MQ, Li JH, Zhang XC, Jiang J, Cheng XH. Inhibition of hsa_circ_0003489 shifts balance from autophagy to apoptosis and sensitizes multiple myeloma cells to Bortezomib via miR-874-3p/HDAC1 axis. J Gene Med. 2021 Sep;23(9):e3329. doi: 10.1002/jgm.3329. (IF: 4.565)
[18] Xue Lei*, Qinglian He*, Ziqi Li, Qian Zou, Pingrong Xu, Haibing Yu, Yuanlin Ding,Wei Zhu#.Cancer stem cells in colorectal cancer and the association with chemotherapy resistance. Medical Oncology. 2021;38:43 (IF: 3.064)
[19] Qinglian He, Ziqi Li, Jinbao Yin, Yuling Li, Yuting Yin, Xue Lei andWei Zhu#. Prognostic significance of autophagy relevant gene markers in colorectal cancer. Front. Oncol. 2021; 11(1542): 1-11. (IF: 6.244)
[20] Qinglian He, Aihua Ye, Weibiao Ye, Xiaomin Liao, Guoqiang Qin, Yongqiang Xu, Yuting Yin, Huanqian Luo, Muhua Yi, Liying Xian, Shihao Zhang, Xiyuan Qin,Wei Zhu#and Yuling Li#. Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1. Cell Death & Disease. 2021;12:576 (IF: 8.469)
[21] Qinglian He*, Ziqi Li, Xue Lei, Qian Zou, Haibing Yu, Yuanlin Ding, Guangxian Xu, andWei Zhu#.The underlying molecular mechanisms and prognostic factors of RNA binding protein in colorectal cancer: A study based on multiple online databases. Cancer Cell International. 2021;21:325. (IF: 5.722)
[22] Qian Zou*, Lei Xue*, Qinglian He, Ziqi Li, Pingrong Xu, Xiujuan Huang, Faqing Tian#, Yuanlin Ding #,Wei Zhu#. Chemokines in Progression, Chemoresistance, Diagnosis and Prognosis of Colorectal Cancer. Front. Immu. 2022; 7; 22 (IF: 8.786)
授权专利：
(1)发明人：朱伟；专利名称：一种细胞划痕用装置；授权时间：2021-2-19；专利号：ZL202020550541.2，中国。
(2)发明人：朱伟；专利名称：一种具有病理切片染色装置；授权时间：2022-4-22；专利号：ZL202123074139.5，中国。